Vir Bio Reports Q3 2026 Financial Results and Gilead Collaboration Details
Vir Bio (VIR) reported its third-quarter 2026 financial results, highlighting a significant narrowing of net losses to $96.3 million ($0.57 per share) compared to $163.1 million in the prior year period. The company maintains a strong liquidity position with $901.3 million in cash and investments as of September 30, 2026, providing an operational runway into the second half of 2028. Key strategic developments include a collaboration with Gilead Sciences involving up to $1.74 billion in potential milestone payments and tiered royalties on solid tumor candidates. Clinical progress remains central to the company's outlook, with top-line data from the ECLIPSE-1 trial expected in Q4 2026 and Phase III studies for VIR-5500 planned for 2027.